Onconetix, Inc. (ONCO) Insider Trading Activity

NASDAQ$6.95
Market Cap
$2.49M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
260 of 846
Rank in Industry
147 of 490

ONCO Insider Trading Activity

ONCO Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$152,875
3
50
Sells
$144,469
3
50

Related Transactions

HRT FINANCIAL LP10 percent owner
3
$152,875
3
$144,469
$8,406

About Onconetix, Inc.

Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.

Insider Activity of Onconetix, Inc.

Over the last 12 months, insiders at Onconetix, Inc. have bought $152,875 and sold $144,469 worth of Onconetix, Inc. stock.

On average, over the past 5 years, insiders at Onconetix, Inc. have bought $152,875 and sold $144,469 worth of stock each year.

Highest buying activity among insiders over the last 12 months: HRT FINANCIAL LP (10 percent owner) — $152,875.

The last purchase of 34,636 shares for transaction amount of $25,284 was made by HRT FINANCIAL LP (10 percent owner) on 2026‑04‑17.

List of Insider Buy and Sell Transactions, Onconetix, Inc.

2026-04-21SaleHRT FINANCIAL LP10 percent owner
49,710
1.4791%
$0.69
$34,300
-85.23%
2026-04-20SaleHRT FINANCIAL LP10 percent owner
94,462
2.8247%
$0.75
$70,847
-86.27%
2026-04-17PurchaseHRT FINANCIAL LP10 percent owner
34,636
0.9972%
$0.73
$25,284
-86.35%
2026-04-16SaleHRT FINANCIAL LP10 percent owner
53,867
1.5101%
$0.73
$39,323
-86.64%
2026-04-15PurchaseHRT FINANCIAL LP10 percent owner
92,554
2.6959%
$0.76
$70,341
-86.60%
2026-04-14PurchaseHRT FINANCIAL LP10 percent owner
74,350
1.3696%
$0.77
$57,250
-88.79%
Total: 6
*Gray background shows transactions not older than one year

ONCO Institutional Investors: Active Positions

Increased Positions3+33.33%14,775+15.13%
Decreased Positions3-33.33%51,371-52.6%
New Positions<1New10,827New
Sold Out Positions2Sold Out28,633Sold Out
Total Postitions90%61,061-37.47%

ONCO Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.